Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases

MLA

Massimo Nicolò, et al. Faricimab: An Investigational Agent Targeting the Tie-2/Angiopoietin Pathway and VEGF-A for the Treatment of Retinal Diseases. Jan. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....768b9ca5966ecc4c391971a433220d04&authtype=sso&custid=ns315887.

APA

Massimo Nicolò, Aldo Vagge, Carlo Enrico Traverso, & Lorenzo Ferro Desideri. (2021). Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases.

Chicago

Massimo Nicolò, Aldo Vagge, Carlo Enrico Traverso, and Lorenzo Ferro Desideri. 2021. “Faricimab: An Investigational Agent Targeting the Tie-2/Angiopoietin Pathway and VEGF-A for the Treatment of Retinal Diseases,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....768b9ca5966ecc4c391971a433220d04&authtype=sso&custid=ns315887.